As the prevalence of type 2 diabetes (T2D) increases globally, the condition and its associatedcomplications are generating considerable—and growing—economic burden on healthcaresystems and societies. Brazil reflects this this trend, facing a rising prevalence of T2D,1,2 with over11.5million people living with the condition, and this figure expected to double by 2040. The potentialconsequences that diabetes could generate on the nation, both in the present and future setting,are a major challenge for all stakeholders. Despite improved diagnosis and advances in treatmentoptions for individuals with T2D, sub-optimal therapy compliance and persistence limit the benefits
derived from these and contribute to avoidable economic and social burden.
This report is part of a publication series examining six countries and their differing stages ofrecognition of T2D as a public health priority. It examines the Brazil-specific burden of T2D and itscomplications, and opportunities in relation to therapy compliance and persistence improvementstrategies. A range of validated, Brazil-specific recommendations to address sub-optimal T2Dtherapy compliance and persistence are put forth for action by government stakeholders, payers,healthcare providers and healthcare administrators and focus on three broad phases of a patientjourney toward optimal compliance and persistence, (i) identify and profile, (ii) activate and, (iii)
sustain. These are all designed to improve T2D therapy compliance and persistence in the Brazilianpopulation, and consequently decrease significant and avoidable economic and societal costs, andimprove quality of life for people living with the condition.
This study is based on research and analysis undertaken by the IMS Consulting Group with supportfrom Lilly Diabetes. The contributions to this report of Andre Fabre Ballalai Ferraz, Andreas Duva,Daniel Houslay, Peter Thomas, Graham Lewis, Adam Collier, Mark Lamotte, Volker Foos, Phil McEwan,Raf De Moor and others at IMS Health are gratefully acknowledged.
